

## FTC v. Actavis - Where do Hatch-Waxman settlements go from here?

SEPTEMBER 19, 2013

On June 17, 2013, the Supreme Court decided *Federal Trade Commission v. Actavis, Inc.*, which resolved a circuit split over the appropriate antitrust standard to apply when evaluating "reverse payment" Hatch-Waxman patent litigation settlements. This decision has significant consequences for settlements in branded vs. generic abbreviated new drug application (ANDA) litigation in the pharmaceutical industry.

WilmerHale Partner Mark Ford is a featured speaker at this Boston Bar Association event, and will be presenting an antitrust analysis of reverse payment settlements in Hatch-Waxman cases.

[READ MORE ABOUT THE EVENT](#)

---

### *Speakers*




**Mark A. Ford**

PARTNER

 [mark.ford@wilmerhale.com](mailto:mark.ford@wilmerhale.com)

 BOSTON


 + 1 617 526 6423

---

## *Related Solutions*

Antitrust and Competition

## *You May Be Interested In*



### **SIFMA Basel III Endgame Roundtable**

APRIL 18, 2024

**SPEAKING ENGAGEMENT**



### **CFTC 2023 Year in Review and a Look Forward Webinar**

APRIL 18, 2024

**WEBINAR**



## Pharmaceutical Compliance Congress (PCC) 2024

APRIL 16–18, 2024

SPEAKING ENGAGEMENT

[VIEW ALL EVENTS](#)